key: cord-0840039-b835kivy
authors: Lau, George; Ward, John W.
title: Synthesis of Liver Associations Recommendations for Hepatology and Liver Transplant Care During the COVID‐19 Pandemic
date: 2020-05-21
journal: Clin Liver Dis (Hoboken)
DOI: 10.1002/cld.972
sha: fbd2594e34b34a2d8ada78a7644ebe8b9ee39921
doc_id: 840039
cord_uid: b835kivy

nan

To this end, all three associations recommend physical distancing by limiting face-to-face consultations to urgent situations, routine patient contact via telemedicine and phone visits, and use of local laboratories and pharmacies to reduce clinic and hospital visits and patient travel. AASLD guidance is most stringent by discouraging clinic entry of anyone with fever or other COVID-19 symptoms and SARS-CoV-2 testing of these patients. All recommend COVID-19 testing of liver transplant donors and recipients and patients with encephalopathy or acute decompensation. Recent data showed that many SARS-CoV-2-infected patients are asymptomatic, yet capable of transmitting the disease. 7 Ideally, all patients with a history of close contact with cases of possible or confirmed COVID-19 or from high-prevalence regions should be tested. APASL recommends SARS-CoV-2 testing based on clinical and epidemiological factors. EASL recommends following an institution's practice. AASLD and APASL describe the personal protective equipment (PPE) requirements for endoscopy and other procedures. Like SARS-CoV-2 testing, the limiting factor is the availability of PPE. Without adequate supply, many elective procedures will need to be canceled.

Modifications of the practice of liver transplantation (LT) are recommended by all three associations. With the potential risks of SARS-CoV-2 transmission, aggravated by the limited supply of PPE and other resources, many governments have restricted elective medical procedures, including LT. However, in the United States, LTs are considered "high-acuity surgery" and can proceed as medically warranted. 8 Elevation of serum transaminase levels is commonly observed in patients with COVID-19, and a hepatologist might therefore be consulted. All of the guidance suggests that the underlying cause of liver injury may be related to SARS-CoV-2 infections, exacerbation of preexisting CLD, or drug-induced hepatotoxicity. AASLD and APASL provide an algorithm to clinical evaluations (Fig. 1) . A key question is whether patients with CLD have a higher risk for severe COVID-19. AASLD and APASL suggest nonalcoholic fatty liver disease (NAFLD) as an independent prognostic factor, and patients with CLD should be prioritized as candidates for COVID-19 drug trials. EASL and AASLD mention that patients with NAFLD are more likely than others to review have other comorbidity risks for severe COVID-19. To date, there is no evidence that patients with stable CLD due to chronic hepatitis B (CHB) or chronic hepatitis C (CHC) have increased susceptibility to SARS-CoV-2 infection. It is controversial whether there is an increased risk for flare-up of CHB or CHC during COVID-19 and whether prophylactic therapy should be started. Both AASLD and APASL recommend continuing treatment for CHB or CHC in patients with COVID-19. APASL recommends prophylactic hepatitis B therapy for those planned for anti-IL-6 or other immunosuppressive therapy. Initiating prophylactic hepatitis C therapy is not recommended. If there is any suggestion of a flare-up, therapy should be initiated in patients who are not already receiving hepatitis B or hepatitis C treatment.

On May 1, 2020, remdesivir, a nucleotide RNA polymerase inhibitor, was authorized by the US Food and Drug Administration under Emergency Use Authorization for treatment of those patients hospitalized with severe COVID-19. 9 APASL and AASLD recommend close monitoring of liver function in patients, especially those with CLD, who are treated with remdesivir. Patients with decompensated CLD and those with alanine aminotransferase (ALT) >5 times upper limit of normal should not be treated with remdesivir.

To avoid SARS-CoV-2 exposures, all associations recommend reducing patient visits and a delay in HCC ultrasound surveillance. It is uncertain whether HCC treatment should be deferred or started as usual in patients with COVID-19 with newly diagnosed HCC, and whether tyrosine kinase inhibitors (TKIs) or checkpoint inhibitors should be stopped in patients with COVID-19 who are already receiving such therapy. Delaying or withdrawing treatment increases the risk for HCC progression with detrimental outcomes, whereas surgical resection may increase risk for transmission to health care personnel, and checkpoint inhibitors might worsen COVID-19 by exacerbating a cytokine storm. AASLD recommends HCC treatments should proceed. EASL recommends locoregional therapies should be postponed whenever possible and immune-checkpoint inhibitor therapy be temporarily withdrawn. TKI in nonsevere COVID-19 should be taken on a case-by-case basis. APASL recommends postponing elective transplant/resection surgery, whereas radiofrequency ablation, transcatheter arterial chemoembolization, TKI, or immunotherapy can be initiated with change of immunotherapy schedules to every 4 to 6 weeks.

Both APASL and AASLD recommend using alternative physical distancing processes for study assessments to reduce SARS-CoV-2 exposure. APASL specifically recommends seeking local regulators and institutional review board approval of the contingency measures during the COVID-19 pandemic, obtaining trial participant's consent, and documentation of all deviations from the contingency measures. These recommendations align with US National Institutes of Health (NIH) revised guidance for NIH-supported clinical research. 10 sUMMarY APASL, AASLD, and EASL strongly recommend changes in patient workflow and clinical procedures to protect HCWs and patients from SARS-CoV-2 infection. Similarly, the associations generally agree on approaches to evaluation and treatment of patients with COVID-19 for liver disease, and management of patients with HCC and post-liver transplant patients with slight differences in the populations targeted for SARS-CoV-2 testing. These recommendations will evolve with further clinical experience and data from randomized controlled trials. For now, the liver associations provide the best available advice for the management of CLD during the COVID-19 pandemic.

Coalition for Global Hepatitis Elimination, The Task Force for Global Health, 330 W. Ponce de Leon Ave

World Health Organization. Guidance for health workers

Infection control guidance for healthcare professionals about coronavirus (COVID-19)

Coronavirus disease (COVID-19) technical guidance: patient management

Clinical practice guidance for hepatology and liver transplant providers during the COVID-19 pandemic: APASL expert panel consensus recommendations

Insights for hepatology and liver transplant providers during the COVID-19 pandemic

Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID Position Paper

Asymptomatic and presymptomatic SARS-CoV-2 infections in residents of a long-term care skilled nursing facility

CMS Adult elective surgery and procedures recommendations: limit all non-essential planned surgeries and procedures, including dental, until further notice

Fact sheet for health care providers: emergency use authorization (EUA) of Remdesivir (GS-5734™)

Guidance for NIH-funded clinical trials and humansubjectsstudiesaffectedbyCOVID-19. Notice Number NOT-OD-20-087